Biomarker quantification was conducted using single molecule array (Simoa) HD‐X Analyzers from Quanterix at the Clinical Neurochemistry Laboratory of Sahlgrenska University Hospital in Sweden. A commercially available assay (Quanterix Neurology‐4 Plex E) was used to simultaneously quantify for Aβ42, Aβ40 (and Aβ42/Aβ40, consequently), NfL, and GFAP.
27 (link) P‐tau231 and p‐tau181 were analyzed using Simoa assays developed at the University of Gothenburg, which have been validated as described elsewhere.
5 (link),
6 (link) To measure p‐tau217, a novel commercially available assay from ALZpath (ALZpathDX) was used.
43 (link) All samples from the same participant were analyzed in the same analytical run, and each sample was quantified in duplicate. Internal quality controls (iQC) at three different concentrations, for each measurand, were analyzed in duplicate in the beginning and end of each run. Before analysis, blood samples were thawed, vortexed, and centrifuged at 4000 × g for 10 minutes as suggested in recent studies.
44 (link),
45 (link)
27 (link) P‐tau231 and p‐tau181 were analyzed using Simoa assays developed at the University of Gothenburg, which have been validated as described elsewhere.
5 (link),
6 (link) To measure p‐tau217, a novel commercially available assay from ALZpath (ALZpathDX) was used.
43 (link) All samples from the same participant were analyzed in the same analytical run, and each sample was quantified in duplicate. Internal quality controls (iQC) at three different concentrations, for each measurand, were analyzed in duplicate in the beginning and end of each run. Before analysis, blood samples were thawed, vortexed, and centrifuged at 4000 × g for 10 minutes as suggested in recent studies.
44 (link),
45 (link)
Free full text: Click here
